This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEB59082_M.jpg
Renowned investor Cathie Wood believes the sector’s capacity to innovate will continue well into 2021 because biopharma companies are now focusing on developing cures for other life-threatening diseases. Given the ageing population in developed parts of the world, combined with inactive lifestyles amid the remote working structure, there is a huge market for therapies for critical ailments. Wood believes DNA sequencing to be the winning approach to solutions to such diseases and that it will revolutionize the healthcare industry.
Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) have made substantial progress in the field of cancer treatment and critical diseases, and are two of the top holdings in Wood’s Ark Genomic Revolution ETF (ARKG).
